中国疫苗对印度变异株有效！
近段时间以来，中国疫苗已在多个国家和地区展示出了十分显著的有效性。
据印尼卫生部长萨迪金介绍，该国卫生部门通过对接种了2剂科兴疫苗接种的约15万名人员进行追踪后发现，科兴疫苗的预防死亡率达到98%。来自巴西方面的数据也表明，在达到98%科兴疫苗接种率后，确诊患者的重症人数和死亡人数快速减少。
随着印度疫情的影响范围持续扩大，近期中国也检测出多例印度输入病例，且感染的是变异毒株。对此，中国疾控中心专家邵一鸣作出回应，称中国现有的疫苗对印度变异毒株有效，可以产生保护作用。
邵一鸣介绍，国家有关部门和防控系统都在密切跟踪这些信息。一旦出现现有疫苗应付不了的变异株，我们国家的灭活疫苗无需改变生产工艺，仅通过在投料端加入新变异株的病毒，就会有新的疫苗投入使用。
针对多地疫苗接种“提速”的现象，邵一鸣表示，当前国内有足够的新冠疫苗供民众接种，随着我国疫苗产能的逐步加速，疫苗接种效率还将持续增长，相信在年内一定可以实现制定的建立群体免疫屏障的目标。
China is likely to realize herd immunity by the end of 2021 with its world-leading vaccination speed, Shao Yiming, chief expert at the Chinese Center for Disease Control and Prevention, said during an interview with CCTV on Tuesday.
"After a significant increase in our vaccine production capacity since the middle of this year, especially in the second half of the year, we will pace up vaccination," Shao said. "I believe we will be able to meet our target of establishing a herd immunity barrier by the end of this year."
The expert also cautioned that vigilance and monitoring cannot be let down, but said China is closely tracking the situation and has the capability of responding to the mutants.
钟南山：未来可能要定期打新冠疫苗
针对当前全球疫情持续反复的现状以及病毒的变异问题，钟南山院士在接受CGTN专访时表示，新冠与人类的长期共存将成为可能。
↓↓↓
他同时强调，若新冠疫苗保护率不足一年，未来像预防流感一样，定期接种新冠疫苗将成为常态。不过鉴于现在多国都出现了病毒变异，具体发展还是要持续观望。
"If the impact of the COVID-19 on human health is slowly reduced, the long-term coexistence of the coronavirus and humans will become possible. We may have to vaccinate regularly as we prevent the flu," said China's top respiratory expert Zhong Nanshan during an interview with CGTN.
中国疫苗接种剂次全球第一
当前全国接种疫苗已经突破4亿两千万剂次，在全球排在第一位。受近日发生的局部疫情的影响，多地居民接种疫苗意愿显著提高，合肥、阜阳等地都已刷新单日接种量最高纪录，全国范围内的疫苗接种进程还将进一步加快。
More than 400 million doses of COVID-19 vaccines had been administered across China as of Sunday, the National Health Commission said Monday. Residents in east China's Anhui Province showed strong willingness to get vaccinated after the recent COVID-19 cluster was reported. Several cities have set new high in daily vaccination records.